大摩发表报告指，对康哲药业2025至2027年各年销售预测分别调高2%、2.5%及2.9%。毛利率就根据去年下半年趋势作下调，预计2025至2027年毛利率分别为70%、69.3%和68.8%。研发费用和销售费用被调高，以计入不断增加的内部研发投资和创新药物推广活动。因此，大摩将康哲药业2025至2027年各年纯利预测分别下调14.8%、14.4%及13.9%，目标价由10.4港元下调至10港元，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.